Case Report: Third-line QL1706, a bifunctional PD-1/CTLA-4 MabPair product, plus chemotherapy for primary small-cell neuroendocrine carcinoma of the ureter
Abstract
BackgroundPrimary small-cell neuroendocrine carcinoma of the ureter is an extremely rare and aggressive malignancy with no established standard treatment strategy, particularly after progression on prior systemic therapy.Case presentationA 52-year-old man with primary ureteral small-cell neuroendocrine carcinoma underwent non-radical surgery followed by six cycles of etoposide, nedaplatin, and tislelizumab, without subsequent maintenance immunotherapy. The postoperative progression-free interval (PFS1) was approximately 39 months. Following recurrence, second-line etoposide and carboplatin were initiated, with tislelizumab reintroduced in the second cycle; the second-line progression-free survival (PFS2) was approximately 7 weeks. Third-line treatment consisted of QL1706, a bifunctional PD-1/CTLA-4 MabPair product comprising iparomlimab and tuvonralimab, combined with nab-paclitaxel and lobaplatin. QL1706 was administered for two cycles and discontinued because the patient declined further QL1706 treatment, whereas chemotherapy was administered for five cycles. Subsequent imaging showed tumor shrinkage, with the response assessed as stable disease. The third-line progression-free survival (PFS3), measured from treatment initiation to documented progression, was approximately 8 months. Treatment-related adverse events were tolerable.ConclusionThis case illustrates that progression after prior PD-1-containing chemoimmunotherapy did not preclude subsequent disease control with a QL1706-containing chemotherapy regimen. The observed outcome supports further investigation of this combination as a potential salvage strategy for recurrent or refractory ureteral small-cell neuroendocrine carcinoma. However, the individual contribution of QL1706 cannot be distinguished from that of concomitant chemotherapy in this single case.
Related
- Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.
- Case Report: Apparent progressive complete mismatch repair protein loss during platinum-based chemotherapy in metastatic rectal neuroendocrine tumour grade 2
- Primary adrenal small cell neuroendocrine carcinoma in a patient with sarcoidosis and synchronous colon adenocarcinoma
- Renal Neuroendocrine Tumor Mimicking Upper Tract Urothelial Carcinoma
- Intracranial metastasis following intrahepatic remission in primary hepatic small cell neuroendocrine carcinoma: a case report
BibTeX
@article{li2026case,
title = {{Case Report: Third-line QL1706, a bifunctional PD-1/CTLA-4 MabPair product, plus chemotherapy for primary small-cell neuroendocrine carcinoma of the ureter}},
author = {Xiaomin Li and Zhe Meng and Yao Liu and Yibing Liu and Qiang Li},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1986625},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1986625},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Third-line QL1706, a bifunctional PD-1/CTLA-4 MabPair product, plus chemotherapy for primary small-cell neuroendocrine carcinoma of the ureter
AU - Xiaomin Li
AU - Zhe Meng
AU - Yao Liu
AU - Yibing Liu
AU - Qiang Li
PY - 2026
DA - 2026/11/03
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1986625
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1986625
AB - BackgroundPrimary small-cell neuroendocrine carcinoma of the ureter is an extremely rare and aggressive malignancy with no established standard treatment strategy, particularly after progression on prior systemic therapy.Case presentationA 52-year-old man with primary ureteral small-cell neuroendocrine carcinoma underwent non-radical surgery followed by six cycles of etoposide, nedaplatin, and tislelizumab, without subsequent maintenance immunotherapy. The postoperative progression-free interval (PFS1) was approximately 39 months. Following recurrence, second-line etoposide and carboplatin were initiated, with tislelizumab reintroduced in the second cycle; the second-line progression-free survival (PFS2) was approximately 7 weeks. Third-line treatment consisted of QL1706, a bifunctional PD-1/CTLA-4 MabPair product comprising iparomlimab and tuvonralimab, combined with nab-paclitaxel and lobaplatin. QL1706 was administered for two cycles and discontinued because the patient declined further QL1706 treatment, whereas chemotherapy was administered for five cycles. Subsequent imaging showed tumor shrinkage, with the response assessed as stable disease. The third-line progression-free survival (PFS3), measured from treatment initiation to documented progression, was approximately 8 months. Treatment-related adverse events were tolerable.ConclusionThis case illustrates that progression after prior PD-1-containing chemoimmunotherapy did not preclude subsequent disease control with a QL1706-containing chemotherapy regimen. The observed outcome supports further investigation of this combination as a potential salvage strategy for recurrent or refractory ureteral small-cell neuroendocrine carcinoma. However, the individual contribution of QL1706 cannot be distinguished from that of concomitant chemotherapy in this single case.
SN - 1663-9812
ER -